Gossamer Bio (GOSS) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

GOSS Stock Forecast


Gossamer Bio stock forecast is as follows: an average price target of $3.75 (represents a 346.43% upside from GOSS’s last price of $0.84) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

GOSS Price Target


The average price target for Gossamer Bio (GOSS) is $3.75 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $2.00. This represents a potential 346.43% upside from GOSS's last price of $0.84.

GOSS Analyst Ratings


Buy

According to 12 Wall Street analysts, Gossamer Bio's rating consensus is 'Buy'. The analyst rating breakdown for GOSS stock is 0 'Strong Buy' (0.00%), 8 'Buy' (66.67%), 4 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Gossamer Bio Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 08, 2022H.C. Wainwright$5.00$2.16131.48%495.24%
Dec 07, 2022Barclays$2.00$2.36-15.25%138.10%
Dec 07, 2022Raymond James$5.00$2.36111.86%495.24%
Dec 06, 2022David HoangSMBC Nikko$3.00$2.3627.12%257.14%
Apr 26, 2022Barclays$12.00$8.4542.01%1328.57%
Apr 26, 2022Raymond James$10.00$9.0810.13%1090.48%

The latest Gossamer Bio stock forecast, released on Dec 08, 2022 by H.C. Wainwright company, set a price target of $5.00, which represents a 131.48% increase from the stock price at the time of the forecast ($2.16), and a 495.24% increase from GOSS last price ($0.84).

Gossamer Bio Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.84$0.84$0.84
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Gossamer Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Gossamer Bio's last price of $0.84. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 18, 2024H.C. WainwrightBuyBuyHold
Sep 12, 2024Piper SandlerOverweightOverweightHold
Jun 24, 2024OppenheimerBuyOutperformInitialise
May 06, 2024GuggenheimPositiveInitialise
May 06, 2024H.C. WainwrightBuyBuyHold
Mar 06, 2024Goldman SachsBuyBuyHold
Mar 07, 2023Raymond JamesOutperformMarket PerformDowngrade
Dec 08, 2022OppenheimerBuyBuyHold
Dec 07, 2022Goldman SachsBuyBuyHold
Dec 07, 2022UBSBuyBuyHold
Dec 07, 2022BarclaysOverweightEqual-WeightDowngrade
Dec 07, 2022SVB LeerinkOutperformOutperformHold
Dec 06, 2022SMBC NikkoNeutralDowngrade
Nov 17, 2022Raymond JamesOutperformOutperformHold
Apr 26, 2022BarclaysOverweightOverweightHold
Apr 26, 2022Zacks Investment ResearchHoldUpgrade
Apr 26, 2022CitigroupOutperformUpgrade

Gossamer Bio's last stock rating was published by H.C. Wainwright on Sep 18, 2024. The company gave GOSS a "Buy" rating, the same as its previous rate.

Gossamer Bio Financial Forecast


Gossamer Bio Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast$23.71M$10.00M$9.48M$9.48M$10.47M$3.56M$3.56M$3.56M$6.83M$8.53M$114.29M
High Forecast$23.71M$10.00M$9.48M$9.48M$10.47M$3.56M$3.56M$3.56M$17.70M$8.53M$114.29M
Low Forecast$23.71M$10.00M$9.48M$9.48M$10.47M$3.56M$3.56M$3.56M$924.02K$8.53M$114.29M
# Analysts11111113633
Surprise %-----------

Gossamer Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GOSS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Gossamer Bio EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11111113633
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict GOSS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Gossamer Bio's previous annual EBITDA (undefined) of $NaN.

Gossamer Bio Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11111113633
Net Income-----------
Avg Forecast$-21.39M$-31.59M$-39.52M$-39.54M$-35.08M$-44.36M$-43.01M$-43.01M$-38.48M$-33.31M$114.68M
High Forecast$-21.39M$-31.59M$-39.52M$-39.54M$-35.08M$-44.36M$-43.01M$-33.95M$-18.11M$-33.31M$114.72M
Low Forecast$-21.39M$-31.59M$-39.52M$-39.54M$-35.08M$-44.36M$-43.01M$-49.80M$-47.53M$-33.31M$114.64M
Surprise %-----------

Gossamer Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GOSS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Gossamer Bio SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11111113633
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Gossamer Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GOSS last annual SG&A of $NaN (undefined).

Gossamer Bio EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11111113633
EPS-----------
Avg Forecast$-0.09$-0.14$-0.17$-0.17$-0.15$-0.20$-0.19$-0.19$-0.17$-0.15$0.51
High Forecast$-0.09$-0.14$-0.17$-0.17$-0.15$-0.20$-0.19$-0.15$-0.08$-0.15$0.51
Low Forecast$-0.09$-0.14$-0.17$-0.17$-0.15$-0.20$-0.19$-0.22$-0.21$-0.15$0.51
Surprise %-----------

According to undefined Wall Street analysts, Gossamer Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GOSS previous annual EPS of $NaN (undefined).

Gossamer Bio Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PASGPassage Bio$0.67$6.00795.52%Buy
BDTXBlack Diamond Therapeutics$2.50$20.00700.00%Buy
FDMT4D Molecular Therapeutics$6.32$38.33506.49%Buy
INZYInozyme Pharma$2.94$16.00444.22%Buy
BMEABiomea Fusion$4.64$23.33402.80%Buy
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
GOSSGossamer Bio$0.87$3.75331.03%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
LYRALyra Therapeutics$0.18$0.50177.78%Hold
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
STOKStoke Therapeutics$12.10$26.50119.01%Buy
ALECAlector$1.89$4.00111.64%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
REPLReplimune Group$11.72$19.0062.12%Buy
KRONKronos Bio$0.96$1.004.17%Buy

GOSS Forecast FAQ


Is Gossamer Bio a good buy?

Yes, according to 12 Wall Street analysts, Gossamer Bio (GOSS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 66.67% of GOSS's total ratings.

What is GOSS's price target?

Gossamer Bio (GOSS) average price target is $3.75 with a range of $2 to $5, implying a 346.43% from its last price of $0.84. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Gossamer Bio stock go up soon?

According to Wall Street analysts' prediction for GOSS stock, the company can go up by 346.43% (from the last price of $0.84 to the average price target of $3.75), up by 495.24% based on the highest stock price target, and up by 138.10% based on the lowest stock price target.

Can Gossamer Bio stock reach $1?

GOSS's average twelve months analyst stock price target of $3.75 supports the claim that Gossamer Bio can reach $1 in the near future.

What are Gossamer Bio's analysts' financial forecasts?

Gossamer Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $21.16M (high $21.16M, low $21.16M), average EBITDA is $0 (high $0, low $0), average net income is $-165M (high $-156M, low $-172M), average SG&A $0 (high $0, low $0), and average EPS is $-0.731 (high $-0.691, low $-0.761). GOSS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $52.68M (high $52.68M, low $52.68M), average EBITDA is $0 (high $0, low $0), average net income is $-132M (high $-132M, low $-132M), average SG&A $0 (high $0, low $0), and average EPS is $-0.583 (high $-0.583, low $-0.583).